Molecular mechanisms by which splice modulator GEX1A inhibits leukaemia development and progression-Reference-Cited by-同舟云学术

Molecular mechanisms by which splice modulator GEX1A inhibits leukaemia development and progression

Published:2022-04-14 Issue:2 Volume:127 Page:223-236
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Sellin Mark^ORCID,Mack Ryan,Rhodes Matthew C.,Zhang Lei,Berg Stephanie,Joshi Kanak,Liu Shanhui,Wei Wei,S. J. Peter Breslin,Larsen Peter,Taylor Richard E.,Zhang Jiwang^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences

Walther Cancer Foundation

U.S. Department of Health & Human Services | National Institutes of Health

Loyola University Chicago

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-022-01796-5.pdf

Reference105 articles.

1. Ebinger S, Ozdemir EZ, Ziegenhain C, Tiedt S, Castro Alves C, Grunert M, et al. Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia. Cancer Cell. 2016;30:849–62.

2. Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017–23.

3. Gbadamosi M, Meshinchi S, Lamba JK. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia. Future Oncol. 2018;14:3199–213.

4. Hospital MA, Green AS, Maciel TT, Moura IC, Leung AY, Bouscary D, et al. FLT3 inhibitors: clinical potential in acute myeloid leukemia. OncoTargets Ther. 2017;10:607–15.

5. Wu H, Wang A, Qi Z, Li X, Chen C, Yu K, et al. Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia. 2016;30:2112–6.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Targeting of RNA Splicing in Cancer;Genes;2023-06-29

2. SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process;Frontiers in Oncology;2023-03-17